Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Yunpeng Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5647-6724; OpenAlex author ID A5045712598. Sources: OpenAlex.

Their work

Papers
26 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 5 papers

Papers 26

  1. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41418-024-01358-7↗
  2. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Co-author DOI 10.1186/s12943-025-02326-6↗
  3. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-025-06581-5↗
  4. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  5. [Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2025.13475↗
  6. The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer. Co-author DOI 10.1155/2023/6891636↗
  7. Establishment and validation of a nomogram based on coagulation parameters to predict the prognosis of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10908-0↗
  8. Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study. Last author DOI 10.1186/s40001-023-01379-x↗
  9. Identification of genomic instability related lncRNA signature with prognostic value and its role in cancer immunotherapy in pancreatic cancer. Co-author DOI 10.3389/fgene.2022.990661↗
  10. [Corrigendum] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2022.12738↗
  11. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.832315↗
  12. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. First author DOI 10.1016/j.biopha.2019.109521↗
  13. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study. Co-author DOI 10.1007/s00423-019-01766-1↗
  14. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Co-author DOI 10.1016/j.canlet.2018.11.007↗
  15. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Co-author DOI 10.1111/cpr.12428↗
  16. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. Co-author DOI 10.1159/000489382↗
  17. miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2018.8941↗
  18. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis. Co-author DOI 10.1016/j.canlet.2017.08.032↗
  19. A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-017-1308-3↗
  20. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0500-x↗
  21. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗
  22. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗
  23. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.8654↗
  24. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Co-author DOI 10.1186/1471-2407-14-738↗
  25. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Co-author DOI 10.1186/1476-4598-13-130↗
  26. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric … Co-author DOI 10.1186/1479-5876-11-262↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jishu Wei · 14 shared papers, 2014–2025 · strength 1.73
  2. Yi Miao · 18 shared papers, 2014–2025 · strength 1.72
  3. Kuirong Jiang · 14 shared papers, 2013–2025 · strength 1.69
  4. Lingdi Yin · 10 shared papers, 2016–2025 · strength 1.19
  5. Wentao Gao · 10 shared papers, 2013–2025 · strength 1.07
  6. Junli Wu · 9 shared papers, 2013–2025 · strength 0.99
  7. Zipeng Lu · 6 shared papers, 2014–2025 · strength 0.75
  8. Jingjing Zhang · 10 shared papers, 2013–2025 · strength 0.74
  9. Qiang Li · 5 shared papers, 2018–2023 · strength 0.72
  10. Xinchun Liu · 6 shared papers, 2016–2025 · strength 0.71
  11. Min Tu · 6 shared papers, 2014–2025 · strength 0.69
  12. Yi Miao · 4 shared papers, 2013–2025 · strength 0.66
  13. Xiaole Zhu · 5 shared papers, 2018–2023 · strength 0.63
  14. Ying Xin · 3 shared papers, 2018–2025 · strength 0.49
  15. Jingjing Zhang · 2 shared papers, 2025 · strength 0.47
  16. Bin Chen · 2 shared papers, 2022–2025 · strength 0.41
  17. Kai Zhang · 2 shared papers, 2023 · strength 0.41
  18. Feng Guo · 2 shared papers, 2023 · strength 0.41
  19. Qiuyang Chen · 3 shared papers, 2018–2025 · strength 0.39
  20. Chuang Yang · 3 shared papers, 2016–2025 · strength 0.39
  21. Zekuan Xu · 5 shared papers, 2013–2025 · strength 0.38
  22. Shangnan Dai · 2 shared papers, 2020–2025 · strength 0.31
  23. Yi Zhu · 4 shared papers, 2014–2020 · strength 0.30
  24. Guangfu Wang · 2 shared papers, 2019–2025 · strength 0.29
  25. Zhuyin Qian · 3 shared papers, 2013–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.